Better Buy: Pfizer (PFE) vs. AbbVie (ABBV)
For Pfizer (NYSE: PFE), 2017 so far has looked better than the past couple of years in terms of stock performance. However, the stock's 9% year-to-date gain isn't anything to jump up and down about. AbbVie's (NYSE: ABBV) performance, on the other hand, warrants plenty of jumping. The stock is up more than 50% and is on track for its best yearly gain ever.
All that's water under the bridge, though. What really matters for investors is how stocks will perform in the future. Both Pfizer and AbbVie have solid potential, but which is the better choice for long-term investors? Here's how the two big pharma stocks compare.
Image source: Getty Images.
Source: Fool.com
AbbVie Inc. Stock
€170.56
1.510%
The stock is an absolute favorite of our community with 32 Buy predictions and no Sell predictions.
As a result the target price of 178 € shows a slightly positive potential of 4.36% compared to the current price of 170.56 € for AbbVie Inc..
